Olaparib is also approved to treat germline BRCA-mutant pancreatic cancer and, consistently, RTx-161 significantly reduced cellular resistance to Olaparib in the pancreatic cancer cell line CAPAN-1, which harbors the BRCA2 6174delT pathogenic deletion mutation and loss of the wild-type BRCA2 allele (Fig. 2e). This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.